The main goal of this large international study is to improve the remission and survival rate of children with relapsed ALL by optimising their treatment. This goal can be reached by integrating a large number of patients into the study.

With the collaboration of 20 countries, about 250 hospitals and small and medium sized enterprises in the field of biotechnology and IT, this study will benefit from the know-how of all the international investigators. Furthermore we are linked to the networks on paediatric oncology, drug development and parent organisations.